S&P 500   5,086.68 (+0.33%)
DOW   38,934.55 (-0.04%)
QQQ   438.37 (+0.71%)
AAPL   180.40 (-0.56%)
MSFT   409.48 (+0.43%)
META   488.27 (+0.88%)
GOOGL   137.11 (+0.54%)
AMZN   175.06 (+1.10%)
TSLA   200.98 (-0.52%)
NVDA   792.59 (+2.06%)
NIO   5.70 (+4.97%)
AMD   190.03 (+7.64%)
BABA   74.23 (-0.48%)
T   17.00 (+0.24%)
F   12.44 (+1.14%)
MU   90.00 (+0.32%)
CGC   3.29 (-2.08%)
GE   156.18 (+0.37%)
DIS   111.32 (+0.47%)
AMC   4.30 (-13.83%)
PFE   26.77 (-1.00%)
PYPL   60.34 (+0.15%)
XOM   104.72 (+0.38%)
S&P 500   5,086.68 (+0.33%)
DOW   38,934.55 (-0.04%)
QQQ   438.37 (+0.71%)
AAPL   180.40 (-0.56%)
MSFT   409.48 (+0.43%)
META   488.27 (+0.88%)
GOOGL   137.11 (+0.54%)
AMZN   175.06 (+1.10%)
TSLA   200.98 (-0.52%)
NVDA   792.59 (+2.06%)
NIO   5.70 (+4.97%)
AMD   190.03 (+7.64%)
BABA   74.23 (-0.48%)
T   17.00 (+0.24%)
F   12.44 (+1.14%)
MU   90.00 (+0.32%)
CGC   3.29 (-2.08%)
GE   156.18 (+0.37%)
DIS   111.32 (+0.47%)
AMC   4.30 (-13.83%)
PFE   26.77 (-1.00%)
PYPL   60.34 (+0.15%)
XOM   104.72 (+0.38%)
S&P 500   5,086.68 (+0.33%)
DOW   38,934.55 (-0.04%)
QQQ   438.37 (+0.71%)
AAPL   180.40 (-0.56%)
MSFT   409.48 (+0.43%)
META   488.27 (+0.88%)
GOOGL   137.11 (+0.54%)
AMZN   175.06 (+1.10%)
TSLA   200.98 (-0.52%)
NVDA   792.59 (+2.06%)
NIO   5.70 (+4.97%)
AMD   190.03 (+7.64%)
BABA   74.23 (-0.48%)
T   17.00 (+0.24%)
F   12.44 (+1.14%)
MU   90.00 (+0.32%)
CGC   3.29 (-2.08%)
GE   156.18 (+0.37%)
DIS   111.32 (+0.47%)
AMC   4.30 (-13.83%)
PFE   26.77 (-1.00%)
PYPL   60.34 (+0.15%)
XOM   104.72 (+0.38%)
S&P 500   5,086.68 (+0.33%)
DOW   38,934.55 (-0.04%)
QQQ   438.37 (+0.71%)
AAPL   180.40 (-0.56%)
MSFT   409.48 (+0.43%)
META   488.27 (+0.88%)
GOOGL   137.11 (+0.54%)
AMZN   175.06 (+1.10%)
TSLA   200.98 (-0.52%)
NVDA   792.59 (+2.06%)
NIO   5.70 (+4.97%)
AMD   190.03 (+7.64%)
BABA   74.23 (-0.48%)
T   17.00 (+0.24%)
F   12.44 (+1.14%)
MU   90.00 (+0.32%)
CGC   3.29 (-2.08%)
GE   156.18 (+0.37%)
DIS   111.32 (+0.47%)
AMC   4.30 (-13.83%)
PFE   26.77 (-1.00%)
PYPL   60.34 (+0.15%)
XOM   104.72 (+0.38%)
NYSE:NVS

Novartis (NVS) Stock Price, News & Analysis

$101.43
-0.79 (-0.77%)
(As of 02:15 PM ET)
Today's Range
$101.09
$102.37
50-Day Range
$98.10
$108.48
52-Week Range
$79.98
$108.78
Volume
1.39 million shs
Average Volume
1.46 million shs
Market Capitalization
$214.99 billion
P/E Ratio
14.13
Dividend Yield
2.24%
Price Target
$104.33

Novartis MarketRank™ Stock Analysis

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
3.1% Upside
$104.33 Price Target
Short Interest
Healthy
0.20% of Float Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
N/A
News Sentiment
0.68mentions of Novartis in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
11.42%
From $7.18 to $8.00 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.38 out of 5 stars

Medical Sector

740th out of 958 stocks

Pharmaceutical Preparations Industry

348th out of 450 stocks

NVS stock logo

About Novartis Stock (NYSE:NVS)

Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. It offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

NVS Stock Price History

NVS Stock News Headlines

Pharmaceutical Stocks - Best Pharmaceutical Stocks to Buy (NVS)
Along with biotechnology and biotech companies, the pharma industry is a major part of the overall healthcare market. Pharmaceutical companies include some of the biggest stock gainers and some of the best growth stocks on the market. The pharmaceutical market has many amazing stocks to watch. The pharma industry may also be a good investment for those looking for dividend stocks since so many of the largest pharmaceutical companies pay a dividend to its shareholders. Though the industry has plenty of potential for growth, investors should also be aware that pharma stocks—especially smaller startups—can be risky. Investors buying pharma stocks should make sure to do their research and only invest in pharma stocks as part of a diversified portfolio.
4 Sky-Rocketing Pharma Stocks to Watch
Rare Earth Elements: The Workhorse of The Tech Revolution
They're the most underrated yet crucial elements of technology. From renewable energy to military defense, Rare Earths are essential pieces of modern technology. Global superpowers and savvy investors are quickly learning just how valuable they truly are.
BMO Capital Markets Begins Coverage on Novartis (NYSE:NVS)
Move Over Magnificent 7, Say Hello to the GRANOLAS
Game-Changing Cancer Tech Nears FDA Completion
In the world of tech advancements, a new player could outshine even AI. It's a revolutionary technology with the aim of transforming cancer detection. Imagine the leap from basic reading glasses to cutting-edge VR; that's the scale of innovation we're talking about. FDA review is in its final stages and it could become the gold standard before we know it.
See More Headlines
Receive NVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novartis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
1/30/2024
Today
2/29/2024
Next Earnings (Estimated)
4/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Employees
76,057
Year Founded
1996

Price Target and Rating

Average Stock Price Target
$104.33
High Stock Price Target
$114.00
Low Stock Price Target
$85.00
Potential Upside/Downside
+2.1%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

Net Income
$14.85 billion
Pretax Margin
19.55%

Debt

Sales & Book Value

Annual Sales
$45.44 billion
Cash Flow
$10.62 per share
Book Value
$22.06 per share

Miscellaneous

Outstanding Shares
2,119,600,000
Free Float
2,119,388,000
Market Cap
$216.69 billion
Optionable
Optionable
Beta
0.56

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Dr. Vasant Narasimhan (Age 48)
    Chief Executive Officer
    Comp: $8.41M
  • Mr. Harry Kirsch (Age 59)
    Chief Financial Officer
    Comp: $4.19M
  • Mr. Victor Bulto
    President of US
  • Dr. Patrick Horber M.D.
    President of International
  • Dr. Steffen Lang Ph.D. (Age 57)
    President of Operations
    Comp: $2.45M
  • Paul Penepent
    Head of Group Financial Reporting and Accounting
  • Dr. Samir Shah M.D. (Age 62)
    Global Head of Investor Relations
  • Dr. Klaus Moosmayer Ph.D. (Age 56)
    Chief Ethics, Risk & Compliance Officer
    Comp: $1.63M
  • Ms. Karen L. Hale (Age 56)
    Chief Legal Officer
    Comp: $2.46M
  • Dr. Robert Kowalski Pharm.D. (Age 56)
    Chief People & Organization Officer
    Comp: $2.21M














NVS Stock Analysis - Frequently Asked Questions

Should I buy or sell Novartis stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" NVS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVS, but not buy additional shares or sell existing shares.
View NVS analyst ratings
or view top-rated stocks.

What is Novartis' stock price target for 2024?

4 Wall Street research analysts have issued 1 year price objectives for Novartis' shares. Their NVS share price targets range from $85.00 to $114.00. On average, they predict the company's share price to reach $104.33 in the next year. This suggests a possible upside of 3.1% from the stock's current price.
View analysts price targets for NVS
or view top-rated stocks among Wall Street analysts.

How have NVS shares performed in 2024?

Novartis' stock was trading at $100.97 on January 1st, 2024. Since then, NVS shares have increased by 0.2% and is now trading at $101.19.
View the best growth stocks for 2024 here
.

Are investors shorting Novartis?

Novartis saw a drop in short interest in January. As of January 31st, there was short interest totaling 3,890,000 shares, a drop of 10.4% from the January 15th total of 4,340,000 shares. Based on an average trading volume of 1,440,000 shares, the days-to-cover ratio is presently 2.7 days. Approximately 0.2% of the shares of the company are short sold.
View Novartis' Short Interest
.

When is Novartis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 23rd 2024.
View our NVS earnings forecast
.

How were Novartis' earnings last quarter?

Novartis AG (NYSE:NVS) announced its earnings results on Tuesday, January, 30th. The company reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.64 by $0.11. The firm earned $11.42 billion during the quarter, compared to the consensus estimate of $11.69 billion. Novartis had a trailing twelve-month return on equity of 29.90% and a net margin of 29.83%. During the same quarter in the prior year, the firm earned $1.51 EPS.

Is Novartis a good dividend stock?

Novartis (NYSE:NVS) pays an annual dividend of $2.27 per share and currently has a dividend yield of 2.20%. The company has been increasing its dividend for 4 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 31.62%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, NVS will have a dividend payout ratio of 28.38% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for NVS.

What is Vas Narasimhan's approval rating as Novartis' CEO?

938 employees have rated Novartis Chief Executive Officer Vas Narasimhan on Glassdoor.com. Vas Narasimhan has an approval rating of 95% among the company's employees. This puts Vas Narasimhan in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Novartis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novartis investors own include Johnson & Johnson (JNJ), Pfizer (PFE), AbbVie (ABBV), Intel (INTC), AT&T (T), Walt Disney (DIS), Gilead Sciences (GILD), Cisco Systems (CSCO), Merck & Co., Inc. (MRK) and NVIDIA (NVDA).

Who are Novartis' major shareholders?

Novartis' stock is owned by many different retail and institutional investors. Top institutional shareholders include Dodge & Cox (0.62%), Primecap Management Co. CA (0.61%), Dimensional Fund Advisors LP (0.29%), Franklin Resources Inc. (0.28%), Goldman Sachs Group Inc. (0.17%) and Principal Financial Group Inc. (0.12%).

How do I buy shares of Novartis?

Shares of NVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Novartis have any subsidiaries?
The following companies are subsidiares of Novartis: 1 A Pharma GmbH, Abadia Retuerta S.A, Admune Therapeutics, Advanced Accelerator Applications, Advanced Accelerator Applications, Advanced Accelerator Applications International SA, Advanced Accelerator Applications S.A., Advanced Accelerator Applications S.r.l., Advanced Accelerator Applications USA Inc., Aeropharm GmbH, Alcon, Alcon – Couvreur NV, Amblyotech, Amblyotech Inc., Arctos Medical, Arctos Medical AG, Australia Pty Ltd, Beijing Novartis Pharma Co. Ltd., BioMedical Research Co. Ltd., CELLforCURE, Cadent Therapeutics, Cadent Therapeutics Cambridge, Cellerys, Cellerys AG, CellforCure, Chiron Corporation, Ciba-Geigy Japan Limited, Co. Ltd, CoStim Pharmaceuticals, CoStim Pharmaceuticals Inc., Coalesce Product Development Limited, Corthera, Development Co. Ltd., EBEWE Pharma Ges.m.b.H Nfg. KG, Encore Vision, Endocyte, Endocyte Inc., Eon Labs Inc., Farmanova Saglik Hizmetleri Ltd, Fougera Pharmaceuticals, Fougera Pharmaceuticals Inc, Gyroscope Therapeutics, HEXAL AG, Hexal, IDB Holland BV, Iberica S.L.U., Ilaçlari Sanayi ve Ticaret A.S, JSC Sandoz, Japat AG, Kedalion Therapeutics Inc., Lek Pharmaceuticals d.d., Lek S.A., Manufacturing Pte Ltd , Navigate BioPharma Services Inc, Neutec Pharma Limited, Novartis (Hellas) S.A.C.I., Novartis (Singapore) Pte Ltd, Novartis (Taiwan) Co. Ltd, Novartis (Thailand) Limited, Novartis Argentina S.A., Novartis Australia Pty Ltd, Novartis Austria GmbH, Novartis Biociências S.A., Novartis Biosciences Perú S.A., Novartis Bioventures AG, Novartis Business Services GmbH, Novartis Capital Corporation, Novartis Chile S.A., Novartis Corporation, Novartis Corporation Sdn. Bhd., Novartis Deutschland GmbH, Novartis Ecuador S.A., Novartis Farma S.p.A., Novartis Farma – Produtos Farmacêuticos S.A., Novartis Farmacéutica S.A, Novartis Farmacéutica S.A. de C.V., Novartis Finance Corporation, Novartis Finance S.A., Novartis Finance Services Ltd, Novartis Finland Oy Espoo, Novartis Gene Therapies, Novartis Gene Therapies EU Limited, Novartis Gene Therapies Inc., Novartis Grimsby Limited, Novartis Groupe France S.A., Novartis Healthcare A/S, Novartis Healthcare Philippines Inc., Novartis Healthcare Private Limited, Novartis Holding AG, Novartis Hungary Healthcare Limited Liability Company, Novartis India Limited, Novartis Inflammasome Research, Novartis Integrated Services Limited, Novartis International AG, Novartis International Pharmaceutical Investment AG, Novartis Investment Ltd, Novartis Investments S.à r.l., Novartis Ireland Limited, Novartis Israel Ltd, Novartis Korea Ltd., Novartis Middle East FZE, Novartis Netherlands B.V., Novartis Neva LLC, Novartis New Zealand Ltd, Novartis Norge AS, Novartis Ophthalmics AG, Novartis Optogenetics Research Inc., Novartis Overseas Investments AG, Novartis Pharma (Logistics) Inc., Novartis Pharma (Pakistan) Limited, Novartis Pharma AG, Novartis Pharma B.V. , Novartis Pharma GmbH, Novartis Pharma GmbH, Novartis Pharma K.K., Novartis Pharma LLC, Novartis Pharma Maroc SA, Novartis Pharma NV, Novartis Pharma Produktions GmbH, Novartis Pharma S.A.E., Novartis Pharma S.A.S., Novartis Pharma Schweiz AG, Novartis Pharma Schweizerhalle AG, Novartis Pharma Services AG, Novartis Pharma Services Romania S.R.L., Novartis Pharma Stein AG, Novartis Pharmaceuticals Canada Inc., Novartis Pharmaceuticals Corporation, Novartis Pharmaceuticals Limited, Novartis Pharmaceuticals UK Limited, Novartis Poland Sp. z o.o., Novartis Portugal S.G.P.S. Lda., Novartis Ringaskiddy Limited, Novartis Saglik Gida ve Tarim Ürünleri Sanayi ve Ticaret A.S, Novartis Saudi Ltd., Novartis Securities Investment Ltd, Novartis Services Inc., Novartis Slovakia s.r.o., Novartis South Africa (Pty) Ltd, Novartis Sverige AB, Novartis UK Limited, Novartis US Foundation, Novartis Vaccines and Diagnostics Inc, Novartis Vietnam Company Limited, Novartis de Colombia S.A., Novartis de Venezuela S.A., Novartis s.r.o., Oriel Therapeutics Inc., PT. Novartis Indonesia, Protez Pharmaceuticals, Pte Ltd, Research Inc, Salutas Pharma GmbH, Sandoz A/S, Sandoz AG, Sandoz B.V., Sandoz Canada Inc., Sandoz Egypt Pharma S.A.E., Sandoz Farmacéutica S.A., Sandoz Farmacêutica Lda., Sandoz GmbH, Sandoz Hungary Limited Liability Company, Sandoz Ilaç Sanayi ve Ticaret A.S., Sandoz Inc, Sandoz Industrial Products S.A, Sandoz International GmbH, Sandoz K.K., Sandoz Limited, Sandoz Manufacturing Inc., Sandoz NV, Sandoz Pharma K.K, Sandoz Pharmaceuticals AG, Sandoz Pharmaceuticals d.d., Sandoz Philippines Corporation, Sandoz Polska Sp. z o.o. , Sandoz Private Limited, Sandoz Pty Ltd, Sandoz S.A. de C.V, Sandoz S.A.S., Sandoz S.R.L., Sandoz S.p.A., Sandoz South Africa (Pty) Ltd, Sandoz Ukraine LLC, Sandoz d.o.o. farmaceutska industrija, Sandoz do Brasil Indústria Farmacêutica Ltda, Sandoz s.r.o., Selexys Pharmaceuticals Corporation, Shanghai Novartis Trading Ltd., Société par actions SANDOZ, Spinifex Pharmaceuticals, The Medicines Company, The Medicines Company, Triangle International Reinsurance Limited, Trinity River Insurance Co Ltd, Vedere Bio, Vedere Bio ll, Xiidra, Ziarco, and Ziarco Group Limited.
Read More
This page (NYSE:NVS) was last updated on 2/29/2024 by MarketBeat.com Staff

From Our Partners